CytomX wins FDA Fast Track for Varseta-M in metastatic colorectal cancer
CytomX Therapeutics announced FDA Fast Track designation for Varseta-M in relapsed/refractory metastatic colorectal cancer.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.